Healthcare resource utilization and costs in individuals who discontinue liraglutide and who switch from liraglutide to once-weekly injectable semaglutide

Xi Tan¹, Brenna L. Brady²; Lin Xie¹; Yurek Paprocki¹

Aim

 To compare healthcare resource utilization (HCRU) and medical costs between people with type 2 diabetes (T2D) who discontinue the once-daily injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide or switch from liraglutide to the once-weekly injectable GLP-1 RA semaglutide.

Introduction

- The increasing prevalence of T2D is further elevating the burden on the US healthcare system due to rising costs associated with disease progression and management.¹⁻³
- Effective therapies, such as GLP-1 RAs, can help control blood glucose and reduce the risk of diabetes-related complications,^{4,5} ultimately helping to manage associated healthcare costs.
- Analyses in T2D cohorts have demonstrated worse glycemic control and increased HCRU and costs among those who discontinued liraglutide vs those who did not.^{6,7}
- Discontinuing a GLP-1 RA without making appropriate treatment adjustments may lead to suboptimal care and increased HCRU, representing a high-risk, high-cost group.^{6–8}
- Switching to an effective medication such as once-weekly semaglutide⁹ may improve clinical and economic outcomes.¹⁰

Methods

- This was an observational cohort study of real-world claims data (MerativeTM MarketScan[®] Commercial and Medicare Database).
- Patients were indexed from January 1, 2018 to March 31, 2020.
- Patients were included if they were aged \geq 18 years at pre-index, had ≥ 2 medical claims for T2D on different days during the pre-index period and no claims for other GLP-1 RAs during the study, or pregnancy or bariatric surgery/hospice prior to index date.
- Outcomes were compared between discontinuers and switchers over the 360-day post-index period using stabilized inverse probability of treatment weighting.
- Discontinuers were individuals who stopped liraglutide with no addition of insulin or other second-line antidiabetic drugs.
- Switchers were individuals who switched to semaglutide within ±90 days of liraglutide discontinuation, used semaglutide for \geq 180 days and had no addition of other second-line antidiabetic drugs or insulin.

Results

Character

Demogra

Age, meai Female se Payer, *n* (%

Commer Medicare

Clinical ch

DCCI, mea DCSI, mea

Pre-index Biguanid

DPP-4i

SGLT-2i Sulfonylu

TZD/AGI

Insulin HCRU

Hospitaliz

Patients No. of ac

Outpatier

ED

Patient No. of v

Outpatie

Patient

No. of v

All-cause Inpatient

ED visits Outpatien Other outp

Total all me

AGI, alpha glucosidase inhibitors; DCCI, Deyo-Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; DPP-4i, dipeptidyl peptidase-4 inhibitor; ED, emergency department; HCRU, healthcare resource utilization; SD, standard deviation; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; SMD, standardized mean difference; TZD, thiazolidinedione; USD, United States dollar

This work was sponsored by Novo Nordisk Inc. The authors acknowledge the medical writing assistance of Ashfield MedComms, an Inizio company (funded by Novo Nordisk) Presented at ISPOR 2025, May 13–16, Montreal, QC, Canada

• Of the 111,815 patients who discontinued liraglutide for T2D in the database, 5,304 met the criteria and were included in the study. • After inverse probability of treatment weighting, characteristics of the two cohorts were well balanced (**Table 1**).


Table 1: Baseline demographics, clinical characteristics, HCRU and costs after weighting for the discontinuer and switcher cohorts

eristic	Discontinuers n = 3,935	Switchers <i>n</i> = 1,369	SMD
aphics			
an (SD), years	53.1 (8.6)	53.3 (8.4)	0.02
sex, n (%)	2,095 (53.2)	740 (54.1)	0.02
(%)			
ercial	3,678 (93.5)	1,277 (93.3)	0.01
re	257 (6.5)	92 (6.7)	0.01
haracteristics			
ean (SD)	2.4 (1.9)	2.4 (1.9)	0.01
ean (SD)	1.0 (1.4)	1.0 (1.3)	0.00
x glucose-lowering medica	tions, <i>n</i> (%)		
des	2,932 (74.5)	1,017 (74.3)	0.01
	438 (11.1)	154 (11.2)	0.00
	1,397 (35.5)	485 (35.4)	0.00
lureas	1,015 (25.8)	346 (25.3)	0.01
Is	334 (8.5)	115 (8.4)	0.00
	1,945 (49.4)	649 (47.4)	0.04
zations			
s with an admission, <i>n</i> (%)	402 (10.2)	127 (9.3)	0.03
idmissions, mean (SD)	0.1 (0.5)	0.1 (0.5)	0.01
nt visits			
ts with a visit, <i>n</i> (%)	1,023 (26.0)	331 (24.2)	0.04
visits, mean (SD)	0.5 (1.5)	0.4 (0.9)	0.05
ent office			
ts with a visit, <i>n</i> (%)	3,928 (99.8)	1,365 (99.7)	0.02
visits, mean (SD)	9.3 (6.7)	9.3 (6.0)	0.01
e healthcare costs, mean (S	D), USD		
t	\$4,690 (26,662)	\$3,703 (17,258)	0.04
	\$509 (2,073)	\$400 (1,331)	0.06
nt office visits	\$1,140 (963)	\$1,167 (880)	0.03
Itpatient services	\$6,685 (26,334)	\$5,059 (14,186)	0.08
medical	\$13,024 (40,409)	\$10,330 (28,069)	0.08

• Over the full post-index period, discontinuers had significantly higher utilization of inpatient and emergency services compared with switchers, with 9.1% vs 5.2% (p<0.001) having ≥1 hospitalization and 25.4% vs 20.7% having ≥ 1 emergency department (ED) visit (*p*=0.001).


• Quarterly analysis of HCRU mirrored that of the full post-index period, with a greater proportion of discontinuers with >1 hospitalization or ED visit compared with switchers (**Figure 1**). • Mean total post-index medical costs were significantly lower for switchers (\$8,513) than for discontinuers (\$13,585, p<0.001), driven by a 2.6-fold

lower inpatient and 1.6-fold lower ED costs (Figure 2).



• Mean total medical costs remained significantly higher for discontinuers compared with switchers in all four quarters of the post-index period (*p*<0.05 for all quarters) (**Figure 3**).

Figure 3: Weighted post-index quarterly medical costs for the discontinuer and switcher cohorts



Q, quarter; USD, United States dollar

Conclusions

- People with T2D who switched from liraglutide to semaglutide had significantly lower HCRU in inpatient and ED services and lower medical costs compared with people who discontinued liraglutide treatment.
- Continued treatment by switching to semaglutide could result in improved clinical and economic outcomes for people with T2D for whom liraglutide is no longer optimal.

EE100

References:

(1) American Diabetes Association. Diabetes Care 2018;41:917–28; (2) Rowley et al. Popul Health Manag 2017;20:6–12; (3) Patel. Diabetes Care 2025;48:15–7 (4) Sposito et al. Cardiovasc Diabetol 2018;17:157; (5) Yeh et al. PLoS One 2023;18:e0278685; (6) Melzer-Cohen et al. Diabetes Ther 2019;10:683–96; (7) Uzoigwe et al. Diabetes Ther 2022;13:1861–74; (8) Buysman et al. J Comp Eff Res 2018;7:89–100; (9) Capehorn et al. Diabetes Metab 2020;46:100–9; (**10**) Jain et al. Diabetes Ther 2021;12:527–36